Get the Stockscreener App
848.35
3.67%
30.05
Argen X Se Adr stock is traded at $848.35, with a volume of 220.97K.
It is up +3.67% in the last 24 hours and down -13.41% over the past month.
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
See More
Previous Close:
$818.30
Open:
$842.46
24h Volume:
220.97K
Relative Volume:
0.39
Market Cap:
$53.35B
Revenue:
$4.16B
Net Income/Loss:
$1.29B
P/E Ratio:
43.32
EPS:
19.5837
Net Cash Flow:
$734.26M
1W Performance:
+3.63%
1M Performance:
-13.41%
6M Performance:
+0.89%
1Y Performance:
+4.01%
1-Day Range:
$838.78
$858.21
1-Week Range:
$798.48
$835.31
52-Week Range:
$661.85
$1,072.75
Argen X Se Adr Stock (ARGX) Company Profile
Compare ARGX vs VRTX, MRNA, REGN, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARGX
Argen X Se Adr
|
848.35 | 53.35B | 4.16B | 1.29B | 734.26M | 19.58 |
VRTX
Vertex Pharmaceuticals Inc
|
509.72 | 129.19B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.78 | 94.93B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.11 | 82.48B | 14.92B | 4.42B | 3.79B | 41.04 |
ONC
Beone Medicines Ltd Adr
|
371.37 | 42.01B | 5.76B | 514.49M | 1.10B | 4.4813 |
Argen X Se Adr Stock (ARGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-26-26 | Upgrade | UBS | Neutral → Buy |
| Aug-24-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-04-26 | Resumed | Guggenheim | Buy |
| Mar-10-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Dec-18-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-24-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-15-25 | Resumed | Truist | Buy |
| Sep-11-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Jul-08-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| May-13-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-17-25 | Upgrade | Bernstein | Mkt Perform → Outperform |
| Mar-12-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-17-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Nov-12-24 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-05-24 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Nov-01-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-01-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-10-24 | Resumed | Raymond James | Strong Buy |
| Oct-04-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-06-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jul-25-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Jul-23-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-20-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jul-31-23 | Initiated | Scotiabank | Sector Perform |
| Jul-24-23 | Downgrade | UBS | Buy → Neutral |
| Jul-17-23 | Resumed | Evercore ISI | Outperform |
| Jun-15-23 | Initiated | Societe Generale | Sell |
| May-31-23 | Initiated | UBS | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-14-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-07-22 | Initiated | William Blair | Outperform |
| Oct-12-22 | Initiated | Oppenheimer | Perform |
| Jul-29-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-28-22 | Resumed | Stifel | Buy |
| May-03-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Oct-29-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Sep-23-21 | Upgrade | Redburn | Neutral → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-23-21 | Initiated | Deutsche Bank | Hold |
| Jul-19-21 | Resumed | Wolfe Research | Outperform |
| Jun-18-21 | Initiated | UBS | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| May-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-23-21 | Initiated | Redburn | Neutral |
| Mar-05-21 | Reiterated | H.C. Wainwright | Neutral |
| Feb-02-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-04-21 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-20 | Initiated | H.C. Wainwright | Neutral |
| Feb-10-20 | Initiated | BofA/Merrill | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Oct-31-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-22-19 | Initiated | JP Morgan | Overweight |
| Sep-27-19 | Initiated | Wells Fargo | Market Perform |
| Sep-16-19 | Resumed | Cowen | Outperform |
| Jun-28-19 | Initiated | Robert W. Baird | Outperform |
| Jan-18-19 | Resumed | SunTrust | Buy |
| Jan-04-19 | Initiated | Morgan Stanley | Overweight |
| Dec-17-18 | Initiated | Goldman | Buy |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Jun-29-18 | Initiated | Nomura | Buy |
| Apr-09-18 | Initiated | SunTrust | Buy |
| Jan-29-18 | Reiterated | JMP Securities | Mkt Outperform |
View All
Argen X Se Adr Stock (ARGX) Latest News
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026 - GlobeNewswire Inc.
argenx Meets Primary Endpoint in Phase II Celiac Disease Study - Zacks Investment Research
HALO Wins Court Order Blocking Merck's Keytruda SC in Europe - Zacks Investment Research
argenx reports Phase 2 FB102 celiac trial met primary endpoint - Mugglehead Investment Magazine
HALO Expands ENHANZE Collaboration & Licensing Deal With ARGX - Zacks Investment Research
10 Wall Street Analysts Think Argenx Stock Is Headed to At Least $1,200 -- Is the Stock a Buy Now? - The Motley Fool
argenx SE (1AE.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx SE (ARGX.BR) Stock Price, News, Quote & History - Yahoo! Finance Canada
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline - GlobeNewswire Inc.
SGIOY Stock Price, Quote & News - Syfe
argenx at wells fargo healthcare conference: broadening beyond vyvgart By Investing.com - Investing.com India
argenx at wells fargo healthcare conference: broadening beyond vyvgart - investing.com
Argenx Se Stock Price Forecast. Should You Buy ARGX? - StockInvest.us
argenx SEADR Key Financial Ratios – Valuation, Profitability & More - Value Research
argenx to Present at Upcoming Investor Conferences - Barchart.com
BNTX Stock Price, Quote & News - Syfe
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportSocial Sentiment - siam.in
argenx (ARGX) Falters: Slides 3.37% as Bulls Defend Key $972 SupportBlue Chip Entry Points - dars.gov.et
argenx SEADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Resilient Argenx stock holds near record highs after Forte Biosciences acquisition - ad-hoc-news.de
Resilient Argenx stock touches fresh all-time high after Forte Biosciences deal - ad-hoc-news.de
Argenx stock hits all-time high at 1059.86 USD By Investing.com - Investing.com South Africa
argenx Completes Acquisition of Forte Biosciences, Inc. - Barchart.com
Forte Biosciences Director David W. Gryska Sells Entire Stake Amid Merger with argenx BV - Kalkine Media
Argenx Completes Acquisition of Forte Biosciences - marketscreener.com
Why is Argen-X stock climbing today? By Investing.com - Investing.com UK
UBS upgrades argenx stock rating on Vyvgart sales outlook By Investing.com - Investing.com India
Why is Argen-X stock climbing today? - investing.com
Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX) - theglobeandmail.com
Argenx keeps climbing, shrugging off Deutsche Bank's reservations - marketscreener.com
Deutsche Bank Downgrades Argenx to Hold, Lifts PT - www.marketscreener.com
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Nigeria
Deutsche Bank downgrades argenx stock to Hold on valuation By Investing.com - Investing.com Australia
Deutsche Bank downgrades argenx stock to Hold on valuation - Investing.com
ETFs Investing in argenx SE Sponsored ADR Stocks - TradingView
Could argenx SE (ARGX)’s Global Scale Give it an Edge Over Zai Lab Limited American Depositary Shares (ZLAB)? - Yahoo Finance
Resilient Argenx stock climbs after positive myositis data and fresh analyst targets - Ad-hoc-news.de
RBC Capital raises argenx stock price target on myositis data - Investing.com
Strong Argenx stock extends rally after Vyvgart trial win and analyst target hikes. - Ad-hoc-news.de
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Sahm
Citizens raises argenx stock price target to $1,200 on trial results - Investing.com
argenx (ARGX) Latest Price Review: Adds 0.52% to Close at $992.99; Key Levels: the Supplied Trading Band Runs From $943.34 to $1,042.64 for the Current SessionMerger Arbitrage - dars.gov.et
Argenx's Positive Vyvgart Data in Autoimmune Indication Supports Growth and FB102 Broadens Portfolio - Morningstar
Resilient Argenx stock jumps after positive Vyvgart Phase 3 data - Ad-hoc-news.de
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com Australia
TD Cowen raises argenx stock price target to $1,353 on myositis outlook - Investing.com
Gold Gains 1%; NY Empire State Manufacturing Index Rises In August - Benzinga
ARGX Stock Price, Quote & Chart - ChartMill
European ADRs Started The Week Slightly Higher In US Trading - Finimize
There are notable gap-ups and gap-downs in today's session. - ChartMill
Argen X Se Adr Stock (ARGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.66%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):